Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

CON vs SGRY: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CON Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 9–1 Matrix Metrics)

CON Overall Winner 6-Pillar Tally: CON 6 – 0 SGRY Matrix Metrics: CON 9 – 1 SGRY

As of Nov 20, 2026, Concentra Group Holdings Parent, Inc. (CON) is the stronger overall head-to-head candidate over Surgery Partners, Inc. (SGRY) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CON carries a Unified Composite Score of 43.5/100 (HOLD) at $41.84 (22.0x Forward P/E, 17.2% operating margin), whereas SGRY carries 29.6/100 (SELL) at $26.78 (N/M Forward P/E, 13.2% operating margin).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CON vs SGRY
CON NYSE Head-to-Head Winner
Concentra Group Holdings Parent, Inc.
Services-Specialty Outpatient Facilities, Nec
$41.84
+0.94% 1D
Market Cap $5.2B
TTM Revenue $2.34B
Forward P/E 22.0x
Beta / 30D Vol 0.52β · 38% Vol
Unified Composite Score
43.5 / 100 HOLD
Tech 31.0 Fund 47.0 Flow 69.0 Mom 41.1
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (8.0% over 20 days), RSI 56
RSI-14: 55.6 · SMA20: $41.80 · SMA50: $38.66
SGRY NASDAQ
Surgery Partners, Inc. Common Stock
Services-General Medical & Surgical Hospitals, Nec
$26.78
+0.34% 1D
Market Cap $3.5B
TTM Revenue $3.36B
Forward P/E N/M
Beta / 30D Vol 0.87β · 166% Vol
Unified Composite Score
29.6 / 100 SELL
Tech 50.0 Fund 24.0 Flow 56.0 Mom 21.1
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (30.5% over 20 days), RSI 84
RSI-14: 84.4 · SMA20: $24.97 · SMA50: $18.56

6-Pillar Scorecard Institutional Category Breakdown (CON 6 – 0 SGRY)

Columns: Metric · CON · SGRY
1. Valuation Multiples CON
Forward P/E 22.0x N/M
Trailing P/E 24.5x N/M
PEG Ratio N/M 1.66x
EV / Revenue 3.1x 1.9x
2. Growth & Scale CON
Revenue Growth (YoY) +8.6% -0.8%
Earnings Growth (YoY) +36.4% +0.0%
TTM Revenue (USD) $2.34B $3.36B
Market Cap $5.2B $3.5B
3. Profitability & Quality CON
Gross Margin 29.9% 22.2%
Operating Margin 17.2% 13.2%
Net Profit Margin 9.3% -2.6%
Return on Equity (ROE) 47.2% 2.1%
4. Balance Sheet & Cash Flow CON
Cash Generation (TTM) $257M $203M
Cash Flow Margin 11.0% 6.0%
Net Cash / Leverage $2.04B Net Debt (4.20x D/E) $2.96B Net Debt (1.99x D/E)
Dividend Yield 0.60% None (0.00%)
5. Options & Positioning CON
Options Structure Phase BREAKOUT SURGE
Current IV / %ile 269.9% (95th %ile) 62.1% (34th %ile)
Put/Call OI Skew 0.79x (Call-Skewed) N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Markup
6. R&D & Supply-Chain Moat CON
OpEx & R&D Intensity 12.7% of Rev ($297M) 9.0% of Rev ($302M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Care Facilities Operator Medical Care Facilities Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CON (9) vs SGRY (1)
Institutional Metric CON SGRY Criterion Row Edge
Market Capitalization
Scale
$5.2B $3.5B Larger Scale CON
Trailing P/E Ratio
Valuation
24.5x N/M Lower Multiple CON
Forward P/E Ratio
Valuation
22.0x N/M Lower Multiple CON
Revenue Growth (YoY)
Growth
+8.6% -0.8% Higher Growth CON
Operating Margin (TTM)
Profitability
17.2% 13.2% Higher Margin CON
Net Profit Margin
Profitability
9.3% -2.6% Higher Margin CON
Return on Equity (ROE)
Capital Efficiency
47.2% 2.1% Higher ROE CON
52-Week Range Position
Momentum
91% ($19–$44) 97% ($11–$27) Stronger Trend SGRY
Beta / 30D Volatility
Risk Regime
0.52β · 38% Vol 0.87β · 166% Vol Lower Realized Risk CON
Unified Institutional Score
Composite Signal
43.5 / 100 (HOLD) 29.6 / 100 (SELL) Higher Composite CON
Trailing 12M Revenue (USD)
Operating Scale
$2.34B $3.36B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
29.9% 22.2% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 3.1x EV/Rev 1.66x PEG · 1.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$257M ($2.04B Net Debt (4.20x D/E)) $203M ($2.96B Net Debt (1.99x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SGRY +63.75 pp
CON: +4.68% · SGRY: +68.43%
3M Horizon SGRY +72.39 pp
CON: +19.58% · SGRY: +91.97%
6M Horizon SGRY +34.61 pp
CON: +65.24% · SGRY: +99.85%
1Y Horizon CON +47.12 pp
CON: +117.58% · SGRY: +70.46%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period CON Revenue SGRY Revenue CON Op. Margin SGRY Op. Margin Margin Leader
FY2018 N/A $1.77B N/A 4.4% SGRY
FY2019 N/A $1.83B N/A 12.9% SGRY
FY2020 N/A $1.86B N/A 9.8% SGRY
FY2021 N/A $2.23B N/A 13.6% SGRY
FY2022 $1.72B $2.54B 15.0% 13.6% CON
FY2023 $1.84B $2.74B 15.6% 12.0% CON
FY2024 $1.90B $3.11B 16.0% 11.2% CON
FY2025 $2.16B $3.31B 15.4% 11.8% CON

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CON BREAKOUT
99d in phase · OBV NEUTRAL
Current IV 269.9%
IV Percentile 95th %ile
Put/Call OI Skew 0.79x (Call-Skewed)
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact CON Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
SGRY SURGE
5d in phase · OBV NEUTRAL
Current IV 62.1%
IV Percentile 34th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact SGRY Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CON Moat Profile High-Margin Pricing Power Moat
Medical Care Facilities Operator
Competes within the Medical Care Facilities value chain with $5.2B market capitalization and 17.2% operating margin.
OpEx & R&D Reinvestment 12.7% of Rev ($297M)
90D Engineering Disclosures 0 Published
SGRY Moat Profile Cyclical / Execution-Driven Positioning
Medical Care Facilities Operator
Competes within the Medical Care Facilities value chain with $3.5B market capitalization and 13.2% operating margin.
OpEx & R&D Reinvestment 9.0% of Rev ($302M)
90D Engineering Disclosures 0 Published

Investor FAQ CON vs SGRY Key Questions & Quantitative Answers

As of Nov 20, 2026, Concentra Group Holdings Parent, Inc. (CON) is the stronger overall head-to-head candidate over Surgery Partners, Inc. (SGRY) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CON carries a Unified Composite Score of 43.5/100 (HOLD) at $41.84 (22.0x Forward P/E, 17.2% operating margin), whereas SGRY carries 29.6/100 (SELL) at $26.78 (N/M Forward P/E, 13.2% operating margin). Technically, CON sits in a Markup phase (RSI 55.6, BREAKOUT options structure) and SGRY sits in a Markup phase (RSI 84.4, SURGE options structure).

CON leads the Growth & Scale pillar: CON posts +8.6% YoY revenue growth and +36.4% YoY earnings growth on $2.34B TTM revenue (29.9% gross margin, 17.2% operating margin), compared with SGRY at -0.8% YoY revenue growth and +0.0% YoY earnings growth on $3.36B TTM revenue (22.2% gross margin, 13.2% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), CON cumulative revenue shifted +25.6% while SGRY shifted +87.0%. In operating R&D and SG&A reinvestment, CON deploys 12.7% of Rev ($297M) (0 90-day corporate R&D disclosures) versus 9.0% of Rev ($302M) (0 disclosures) for SGRY.

CON screens cheaper on headline valuation multiples. CON trades at 22.0x Forward P/E, 24.5x Trailing P/E, N/M PEG, and 3.1x EV/Revenue (11.0% FCF margin), whereas SGRY trades at N/M Forward P/E, N/M Trailing P/E, 1.66x PEG, and 1.9x EV/Revenue (6.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CON (47.2% ROE) versus SGRY (2.1% ROE) capital efficiency.

In options market volatility and institutional positioning, CON carries 269.9% implied volatility (95th %ile, Extreme (>80th %ile)), a 0.79x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKOUT options structure phase (0.52β · 38% Vol realized risk). By comparison, SGRY carries 62.1% implied volatility (34th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a SURGE options structure phase (0.87β · 166% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.